Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FBXW7 |
Variant | G499Vfs*25 |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | FBXW7 G499Vfs*25 indicates a shift in the reading frame starting at amino acid 499 and terminating 25 residues downstream causing a premature truncation of the 707 amino acid Fbxw7 protein (UniProt.org). Due to the loss of multiple WD domains (UniProt.org), G499Vfs*25 is predicted to lead to a loss of Fbxw7 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 inact mut FBXW7 G499Vfs*25 |
Transcript | NM_033632.3 |
gDNA | chr4:g.152326156delC |
cDNA | c.1496delG |
Protein | p.G499Vfs*25 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001349798.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_024454123.2 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_024454124.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
NM_018315.4 | chr4:g.(152324227_152324304) | c.(1495_1572) | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_011532088.2 | chr4:g.(152322932_152323009) | c.(1495_1572) | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_024454126.2 | chr4:g.(152322932_152323009) | c.(1495_1572) | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
NM_018315 | chr4:g.(152324227_152324304) | c.(1495_1572) | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
NM_033632 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_011532084.2 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
NM_001349798.2 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_011532085.3 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_017008362 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_011532084 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_011532085.2 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
NM_018315.5 | chr4:g.(152324227_152324304) | c.(1495_1572) | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_011532088 | chr4:g.(152322932_152323009) | c.(1495_1572) | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_024454123.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_011532084.3 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_024454122.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_047415898.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_047415901.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_047415899.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_024454121.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_047415897.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_011532085 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_024454126.1 | chr4:g.(152322932_152323009) | c.(1495_1572) | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_047415900.1 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
XM_011532083 | chr4:g.152326156delC | c.1496delG | p.G499Vfs*25 | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|